The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Mesothelin domain-specific monoclonal antibodies and use thereof (Patent number:9803022)
 
Idrees Mian
No Relationships to Disclose
 
Cathy Wagner
No Relationships to Disclose
 
Yvonne Mallory
No Relationships to Disclose
 
Maria Agra
No Relationships to Disclose
 
Emerson Padiernos
No Relationships to Disclose
 
Manjistha Sengupta
No Relationships to Disclose
 
Betsy Morrow
No Relationships to Disclose
 
Jun S. Wei
No Relationships to Disclose
 
Anish Thomas
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Javed Khan
Patents, Royalties, Other Intellectual Property - Monoclonal antibody-based therapeutics targeting fibroblast growth factor receptor 4 (FGFR4) for potential treatment of human cancers expressing FGFR4
 
Azam Ghafoor
No Relationships to Disclose